Vasoactive intestinal peptide as a healing mediator in Crohn's disease

被引：37

作者：

Arranz, A. ^{[1
]}

Abad, C. ^{[3
]}

Juarranz, Y. ^{[1
]}

Leceta, J. ^{[1
]}

Martinez, C. ^{[2
]}

Gomariz, P. ^{[1
]}

机构：

[1] Univ Complutense, Fac Biol, Dept Cellular Biol, ES-28040 Madrid, Spain

[2] Univ Complutense, Fac Med, Dept Cellular Biol, ES-28040 Madrid, Spain

[3] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Canc Ctr, Mental Retardat Res Ctr,Semel Inst Neurosci, Los Angeles, CA 90095 USA

来源：

NEUROIMMUNOMODULATION | 2008年 / 15卷 / 01期

关键词：

vasoactive intestinal peptide; autoimmunity; Crohn's disease; inflammation;

D O I：

10.1159/000135623

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide (VIP/PACAP) system is considered as a paradigm for the use of a neuroendocrine-immune mediator in therapy. We review the role of VIP in 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis as a murine model of Crohn's disease. VIP treatment led to the recovery of clinical factors, the amelioration of parameters related to the recruitment and traffic of cell populations, and the balance of inflammatory mediators derived from granulocytes, antigen-presenting cells and T lymphocytes including Th1, Th2 and Th17. Finally, the most recent data validate its therapeutic role through the modulation of TLR2 and 4 receptors. Copyright (C) 2008 S. Karger AG, Basel.

引用

页码：46 / 53

页数：8

共 28 条

[21] Anti-interleukin-12 antibody for active Crohn's disease [J].

Mannon, PJ ;

Fuss, IJ ;

Mayer, L ;

Elson, CO ;

Sandborn, WJ ;

Present, D ;

Dolin, B ;

Goodman, N ;

Groden, C ;

Hornung, RL ;

Quezado, M ;

Neurath, MF ;

Salfeld, J ;

Veldman, GM ;

Schwertschlag, U ;

Strober, W .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (20) :2069-2079

[22] Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation [J].

Mizoguchi, A ;

Mizoguchi, E ;

Takedatsu, H ;

Blumberg, RS ;

Bhan, AK .

IMMUNITY, 2002, 16 (02) :219-230

[23] Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease [J].

Olson, TS ;

Bamias, G ;

Naganuma, M ;

Rivera-Nieves, J ;

Burcin, TL ;

Ross, W ;

Morris, MA ;

Pizarro, TT ;

Ernst, PB ;

Cominelli, F ;

Ley, K .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (03) :389-398

[24] MECHANISMS OF DISEASE Inflammatory Bowel Disease [J].

Abraham, Clara ;

Cho, Judy H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (21) :2066-2078

[25] IL-17 family cytokines and the expanding diversity of effector T cell lineages [J].

Weaver, Casey T. ;

Hatton, Robin D. ;

Mangan, Paul R. ;

Harrington, Laurie E. .

ANNUAL REVIEW OF IMMUNOLOGY, 2007, 25 :821-852

[26] Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets [J].

Wei, B ;

Velazquez, P ;

Turovskaya, O ;

Spricher, K ;

Aranda, R ;

Kronenberg, M ;

Birnbaumer, L ;

Braun, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (06) :2010-2015

[27] Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study [J].

Winter, TA ;

Wright, J ;

Ghosh, S ;

Jahnsen, J ;

Innes, A ;

Round, P .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (11-12) :1337-1346

[28] Unravelling the pathogenesis of inflammatory bowel disease [J].

Xavier, R. J. ;

Podolsky, D. K. .

NATURE, 2007, 448 (7152) :427-434

← 1 2 3 →